Copyright
©The Author(s) 2016.
World J Respirol. Mar 28, 2016; 6(1): 42-48
Published online Mar 28, 2016. doi: 10.5320/wjr.v6.i1.42
Published online Mar 28, 2016. doi: 10.5320/wjr.v6.i1.42
Table 5 Pretreatment parameters based on the presence or absence of an acute exacerbation of idiopathic pulmonary fibrosis
| AE-IPF | P1 | ||
| + (n = 7) | - (n = 10) | ||
| CRP (mg/dL) | 0.51 (0.14-15.0) | 3.43 (0.15-11.1) | 0.77 |
| LDH (IU/L) | 191 (132-399) | 205 (163-969) | 0.73 |
| KL-6 (U/mL) | 603 (285-1373) | 683 (381-2340) | 0.56 |
| SP-D (ng/dL) | 88.3 (69.1-457) | 101 (58.9-139) | 1.00 |
| PaO2 (mmHg) | 77.1 (75.0-85.3) | 76.8 (69.0-91.7) | 0.78 |
| %VC (%) | 100.1 (83.7-131.1) | 83.6 (68.0-115.7) | 0.07 |
| %DLCO (%) | 58.9 (49.5-78.3) | 65.3 (58.3-92.2) | 0.25 |
| 6MWT: Minimum SpO2 (%) | 93 (90-98) | 93 (90-95) | 0.77 |
- Citation: Ebi N, Tokunaga S, Itoh K, Okamoto I, Edakuni N, Fujii S, Watanabe K, Hayashi S, Maeyama T, Nakanishi Y. Multicenter cooperative observational study of idiopathic pulmonary fibrosis with non-small cell lung cancer. World J Respirol 2016; 6(1): 42-48
- URL: https://www.wjgnet.com/2218-6255/full/v6/i1/42.htm
- DOI: https://dx.doi.org/10.5320/wjr.v6.i1.42